Efficacy and safety of noradrenalin reuptake inhibitor augmentation therapy for schizophrenia: A meta-analysis of double-blind randomized placebo-controlled trials

Taro Kishi, Tomohiko Mukai, Yuki Matsuda, Masatsugu Moriwaki, Nakao Iwata

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: We performed an updated meta-analysis of noradrenalin reuptake inhibitor (NRI) augmentation therapy in patients with schizophrenia treated with antipsychotics based on a previous meta-analysis (Singh etal.). Methods: PubMed, Cochrane Library databases, and PsycINFO citations were searched from their inception to June 10, 2013 without language restrictions. We conducted a systematic review and meta-analysis of individual patient data from randomized controlled trials comparing NRI augmentation therapy with placebo. The outcome measure for efficacy was the psychopathology of schizophrenia and the measures for safety were discontinuation rate and several side effects. We used standardized mean differences (SMD) to estimate treatment effects for continuous variables, and risk ratios (RR) for dichotomous variables, with their 95% confidence intervals (CIs). A random-effects model was used. Results: Nine studies (4 atomoxetine studies, 3 reboxetine studies, 1 reboxetine-betahistine combination study and 1 mazindol study, total n= 298) were identified. No statistically significant effects of NRI augmentation therapy on overall (p= 0.90), positive (p= 0.81), and negative (p= 0.89) symptoms were found. NRI augmentation therapy was marginally superior to placebo for efficacy of depressive symptoms (SMD = -1.08, p= 0.05). Dropout due to all-cause (p= 0.70), inefficacy (p= 0.64), or adverse events (p= 0.18) was similar in both groups. NRI augmentation therapy showed a significantly lower increase or larger reduction in body weight than placebo (SMD = -0.47, p= 0.03). Reboxetine augmentation was associated with less weight gain that placebo in antipsychotic treated schizophrenia patients (SMD = -0.78, p= 0.0001). Conclusion: NRIs may exert an effect on depressive symptoms, and seem to be well-tolerated treatments.

Original languageEnglish
Pages (from-to)1557-1563
Number of pages7
JournalJournal of Psychiatric Research
Volume47
Issue number11
DOIs
Publication statusPublished - 01-01-2013

Fingerprint

Meta-Analysis
Schizophrenia
Norepinephrine
Randomized Controlled Trials
Placebos
Safety
Therapeutics
Antipsychotic Agents
Betahistine
Mazindol
Depression
Psychopathology
PubMed
Libraries
Weight Gain
Language
Odds Ratio
Body Weight
Outcome Assessment (Health Care)
Databases

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

@article{262b9e56b9b549e2a345fa0f424d9d24,
title = "Efficacy and safety of noradrenalin reuptake inhibitor augmentation therapy for schizophrenia: A meta-analysis of double-blind randomized placebo-controlled trials",
abstract = "Background: We performed an updated meta-analysis of noradrenalin reuptake inhibitor (NRI) augmentation therapy in patients with schizophrenia treated with antipsychotics based on a previous meta-analysis (Singh etal.). Methods: PubMed, Cochrane Library databases, and PsycINFO citations were searched from their inception to June 10, 2013 without language restrictions. We conducted a systematic review and meta-analysis of individual patient data from randomized controlled trials comparing NRI augmentation therapy with placebo. The outcome measure for efficacy was the psychopathology of schizophrenia and the measures for safety were discontinuation rate and several side effects. We used standardized mean differences (SMD) to estimate treatment effects for continuous variables, and risk ratios (RR) for dichotomous variables, with their 95{\%} confidence intervals (CIs). A random-effects model was used. Results: Nine studies (4 atomoxetine studies, 3 reboxetine studies, 1 reboxetine-betahistine combination study and 1 mazindol study, total n= 298) were identified. No statistically significant effects of NRI augmentation therapy on overall (p= 0.90), positive (p= 0.81), and negative (p= 0.89) symptoms were found. NRI augmentation therapy was marginally superior to placebo for efficacy of depressive symptoms (SMD = -1.08, p= 0.05). Dropout due to all-cause (p= 0.70), inefficacy (p= 0.64), or adverse events (p= 0.18) was similar in both groups. NRI augmentation therapy showed a significantly lower increase or larger reduction in body weight than placebo (SMD = -0.47, p= 0.03). Reboxetine augmentation was associated with less weight gain that placebo in antipsychotic treated schizophrenia patients (SMD = -0.78, p= 0.0001). Conclusion: NRIs may exert an effect on depressive symptoms, and seem to be well-tolerated treatments.",
author = "Taro Kishi and Tomohiko Mukai and Yuki Matsuda and Masatsugu Moriwaki and Nakao Iwata",
year = "2013",
month = "1",
day = "1",
doi = "10.1016/j.jpsychires.2013.07.003",
language = "English",
volume = "47",
pages = "1557--1563",
journal = "Journal of Psychiatric Research",
issn = "0022-3956",
publisher = "Elsevier Limited",
number = "11",

}

Efficacy and safety of noradrenalin reuptake inhibitor augmentation therapy for schizophrenia : A meta-analysis of double-blind randomized placebo-controlled trials. / Kishi, Taro; Mukai, Tomohiko; Matsuda, Yuki; Moriwaki, Masatsugu; Iwata, Nakao.

In: Journal of Psychiatric Research, Vol. 47, No. 11, 01.01.2013, p. 1557-1563.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy and safety of noradrenalin reuptake inhibitor augmentation therapy for schizophrenia

T2 - A meta-analysis of double-blind randomized placebo-controlled trials

AU - Kishi, Taro

AU - Mukai, Tomohiko

AU - Matsuda, Yuki

AU - Moriwaki, Masatsugu

AU - Iwata, Nakao

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Background: We performed an updated meta-analysis of noradrenalin reuptake inhibitor (NRI) augmentation therapy in patients with schizophrenia treated with antipsychotics based on a previous meta-analysis (Singh etal.). Methods: PubMed, Cochrane Library databases, and PsycINFO citations were searched from their inception to June 10, 2013 without language restrictions. We conducted a systematic review and meta-analysis of individual patient data from randomized controlled trials comparing NRI augmentation therapy with placebo. The outcome measure for efficacy was the psychopathology of schizophrenia and the measures for safety were discontinuation rate and several side effects. We used standardized mean differences (SMD) to estimate treatment effects for continuous variables, and risk ratios (RR) for dichotomous variables, with their 95% confidence intervals (CIs). A random-effects model was used. Results: Nine studies (4 atomoxetine studies, 3 reboxetine studies, 1 reboxetine-betahistine combination study and 1 mazindol study, total n= 298) were identified. No statistically significant effects of NRI augmentation therapy on overall (p= 0.90), positive (p= 0.81), and negative (p= 0.89) symptoms were found. NRI augmentation therapy was marginally superior to placebo for efficacy of depressive symptoms (SMD = -1.08, p= 0.05). Dropout due to all-cause (p= 0.70), inefficacy (p= 0.64), or adverse events (p= 0.18) was similar in both groups. NRI augmentation therapy showed a significantly lower increase or larger reduction in body weight than placebo (SMD = -0.47, p= 0.03). Reboxetine augmentation was associated with less weight gain that placebo in antipsychotic treated schizophrenia patients (SMD = -0.78, p= 0.0001). Conclusion: NRIs may exert an effect on depressive symptoms, and seem to be well-tolerated treatments.

AB - Background: We performed an updated meta-analysis of noradrenalin reuptake inhibitor (NRI) augmentation therapy in patients with schizophrenia treated with antipsychotics based on a previous meta-analysis (Singh etal.). Methods: PubMed, Cochrane Library databases, and PsycINFO citations were searched from their inception to June 10, 2013 without language restrictions. We conducted a systematic review and meta-analysis of individual patient data from randomized controlled trials comparing NRI augmentation therapy with placebo. The outcome measure for efficacy was the psychopathology of schizophrenia and the measures for safety were discontinuation rate and several side effects. We used standardized mean differences (SMD) to estimate treatment effects for continuous variables, and risk ratios (RR) for dichotomous variables, with their 95% confidence intervals (CIs). A random-effects model was used. Results: Nine studies (4 atomoxetine studies, 3 reboxetine studies, 1 reboxetine-betahistine combination study and 1 mazindol study, total n= 298) were identified. No statistically significant effects of NRI augmentation therapy on overall (p= 0.90), positive (p= 0.81), and negative (p= 0.89) symptoms were found. NRI augmentation therapy was marginally superior to placebo for efficacy of depressive symptoms (SMD = -1.08, p= 0.05). Dropout due to all-cause (p= 0.70), inefficacy (p= 0.64), or adverse events (p= 0.18) was similar in both groups. NRI augmentation therapy showed a significantly lower increase or larger reduction in body weight than placebo (SMD = -0.47, p= 0.03). Reboxetine augmentation was associated with less weight gain that placebo in antipsychotic treated schizophrenia patients (SMD = -0.78, p= 0.0001). Conclusion: NRIs may exert an effect on depressive symptoms, and seem to be well-tolerated treatments.

UR - http://www.scopus.com/inward/record.url?scp=84884418279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884418279&partnerID=8YFLogxK

U2 - 10.1016/j.jpsychires.2013.07.003

DO - 10.1016/j.jpsychires.2013.07.003

M3 - Article

C2 - 23899496

AN - SCOPUS:84884418279

VL - 47

SP - 1557

EP - 1563

JO - Journal of Psychiatric Research

JF - Journal of Psychiatric Research

SN - 0022-3956

IS - 11

ER -